In the formulation development, scale-up manufacturing, and generic drug registration of topical semisolid dosage forms (ointments, creams, gels, lotions) and transdermal delivery systems, in vitro release testing (IVRT) and in vitro permeation testing (IVPT) are two core technologies used by international regulations (US FDA, EMA, USP, TFDA) to assess the microstructure, batch consistency, and bioequivalence (BE) of prescriptions.

The two differ fundamentally in their experimental objectives, regulatory positioning, membrane material selection, drug administration conditions, and data interpretation. The following is a full text comparison and in-depth analysis based on the latest international guidelines and experimental practices:

I. Core Evaluation Goals and Positioning of the Experiment

1. In vitro skin penetration testing (IVPT)

• Assessment of in vitro-in vivo correlation (IVIVC): Simulating human physiological conditions to predict the transdermal absorption kinetics and bioavailability of drugs in vivo.

• Assessing the ability to cross the stratum corneum barrier: accurately quantifying the rate and total amount of drug penetration into the epidermis, dermis, or into receptor circulation.

• Comparison of prescription and dosage form penetration kinetics: evaluating the degree to which different excipients, penetration enhancers, microemulsions or carrier systems improve the efficiency of transdermal drug delivery.

• New Chemical Entities (NCE) Screening: A tool for screening early-stage lead compounds for novel drug candidates for topical and transdermal absorption.

• Local bioequivalence (BE) exemption evidence: In accordance with the US FDA Product Specific Guidelines (PSG), the rate and extent of penetration of the generic drug (Test Product) and the original manufacturer's reference drug (RLD) to reach the target site through human skin are compared as key regulatory data to replace expensive clinical endpoint BE trials.

2. In vitro release testing: IVRT (In Vitro Release Testing)

• Matrix release rate assessment: to evaluate the effect of changes in inactive excipients in the prescription on the thermodynamic diffusion release of the drug from the semi-solid matrix.

• Sameness verification of the prescription matrix: For prescriptions with the same main component and similar excipients, verify the consistency of their thermodynamic activity and matrix microstructure.

• Key process parameters (CPP) impact monitoring: Evaluate the impact of process differences such as homogenization shear rate, emulsification temperature, and cooling curve on the microstructure of semi-solid matrix.

• Batch-to-batch reproducibility and stability monitoring: as part of quality control (QC) batch release testing, and for monitoring the physical and chemical stability of the matrix of pharmaceutical products during long-term and accelerated stability testing.

• Basis for scale-up production and post-market changes: Statutory testing methods that comply with the US FDA SUPAC-SS (Scale-up and Post-Market Changes for Semi-Solid Formulations) guidelines.

II. Comparison and Analysis of Key Experimental Parameters and Operating Conditions

1. Testing the membrane material

• IVPT: Uses ex vivo skin tissue with biological barrier function. Regulations predominantly recommend split-thickness human skin (usually taken from donated skin from abdominal or back surgeries, with a thickness of approximately 250 to 500 µm). If animal skin (such as pig ear skin or miniature pig skin) is used, sufficient validation must be provided to demonstrate that its penetration impedance is equivalent to that of human skin.

• IVRT: Uses a non-biologically active, inert synthetic microporous membrane (such as PVDF, PTFE, PES, Polysulfone, or Nylon, with a pore size typically of 0.45 µm). The membrane material serves only as a physical boundary separating the formulation matrix and the acceptor medium; the membrane itself must not chemically adsorb drug molecules, nor should it impede mass transfer for drug diffusion.

2. Receptor Solution

• IVPT: Physiological media are used. A phosphate buffer (PBS, pH 7.4) is routinely used, with the addition of 0.01% sodium azide (NaN₃) and other antibacterial agents to prevent skin tissue decay. To maintain the integrity of the skin tissue structure, high concentrations of organic solvents are avoided; for poorly soluble drugs, trace amounts of bovine serum albumin (BSA) or appropriate amounts of mild and nonionic surfactants (such as Volpo or Tween-20) can be added to maintain the funnel conditions.

• IVRT: Employs a high-solubility media. Prefers water-organic miscible systems (e.g., solutions containing methanol, ethanol, isopropanol, etc.) to provide a powerful infinite sink condition, where the drug release rate depends solely on the thermodynamic diffusion within the matrix, unaffected by media saturation.

3. Sampling Mode

• IVPT: Large volume sampling or continuous flow path collection is used. If a vertical diffusion cell (VDC) is used, a larger proportion of the volume is usually drawn each time or the entire volume of the replacement acceptor fluid is emptied. If a flow-through cell (FDC) is used, the acceptor medium is continuously pumped at a low flow rate, flows through the bottom of the diffusion cell, and is then continuously collected directly into the sample vial.

• IVRT: Aliquot Sampling is employed. Regardless of whether a vertical diffusion cell or an immersion cell is used, a fixed micro-volume (e.g., 0.2 to 1.0 mL) is extracted at each set time point, and then immediately replaced with a fresh medium of equal volume and temperature.

4. Equipment

• IVPT primarily uses vertical diffusion cells (VDC/Franz Cell) or next-generation flow-through cells (FDC).

• IVRT: Primarily uses a vertical diffusion cell (VDC) or immersion cell module (Immersion Cell, placed in a USP 2-paddle dissolution cup).

5. Dosage Regimen

• IVPT: Finite Dosing, with an application rate of 5 to 15 mg/cm². This condition strictly simulates the actual application thickness in human clinical practice. The medication is usually unoccluded after administration, allowing the volatile solvent in the prescription to evaporate naturally, fully revealing the film formation and sedimentation dynamics of the drug on the skin surface.

• IVRT: Infinite Dosing, involves filling the receiver tank with a large excess (the excess thickness is typically > 2 mm). After administration, the tank is usually sealed to prevent evaporation of volatile solvents and maintain a stable chemical concentration gradient.

6. Experiment Duration and Sampling Frequency

• IVPT: Long-term testing, usually at least 24 hours, but special sustained-release patches or long-acting formulations can extend it to 48-72 hours. The sampling interval is longer, and the frequency is usually more than once every hour (e.g., at 1, 2, 4, 8, 12, 16, 20, and 24 hours).

• IVRT: Short-duration test, typically completed within 4 to 6 hours. Sampling intervals are close together, with a frequency typically less than or equal to once every 30 minutes (e.g., at minutes 15, 30, 45, 60, 90, 120, 180, and 240) to accurately capture the linear slope in the early stages of release.

7. Definition of Time Zero

• IVPT: The instant the sample touches the skin surface is taken as the zero point of the test time.

• IVRT: The instant when the synthetic membrane comes into contact with the surface of the recipient fluid is taken as the zero point of the test time.

8. Receptor fluid drug concentration levels and analytical techniques

• IVPT: The receptor fluid concentration is extremely low, in the trace range (pg/mL to ng/mL). Due to the barrier of the stratum corneum, the penetration amount is very small, and the analytical detection end must rely on an ultra-high sensitivity HPLC/UPLC tandem three-segment quadrupole mass spectrometer (LC-MS/MS).

• IVRT: The receptor fluid concentration is high, in the high concentration range (µg/mL to mg/mL). Because the synthetic membrane has no mass transfer resistance, the drug is rapidly released, and the analytical detection end can accurately quantify the drug using conventional HPLC/UPLC with ultraviolet (UV) light or diode array (DAD) detectors.

9. Replicates and Statistical Design

• IVPT: Given the significant individual differences in human skin, regulations require at least 4 independent donors, and each donor must provide at least 4 parallel replicate diffusion pools (a total of at least 16 pools; most rigorous studies recommend 6 donors × 4 replicates for a total of 24 pools).

• IVRT: Due to the excellent reproducibility of the synthetic membrane, the release rate is usually statistically compared by using a group of 6 or 12 diffusion cells.

10. Key Output Data and Judgment Indicators

• IVPT:

• Flux Profile (J).

• Peak maximum penetration flux (Jmax).

• Peak time (Tmax).

• Total cumulative penetration exposure (AUC 0-t).

• Bioequivalence determination: After logarithmic transformation of Jmax and AUC, the 90% confidence interval (CI) of the ratio of the geometric mean of the test drug to that of the control drug is calculated.

• IVRT:

• Release rate (slope K): The linear slope obtained by plotting the cumulative release per unit area (Q) against the square root of time (Higuchi model, the linear correlation coefficient r must be ≥ 0.97).

• SUPAC equivalence determination: The 90% confidence interval of the release rate ratio between the experimental group and the control group must fall entirely within the range of 75.00% to 133.33%.

III. In-depth analysis of the data dynamics models of IVRT and IVPT

1. Higuchi release kinetic model of IVRT

The theoretical framework of IVRT is derived from the classic Higuchi equation. Under infinite dosage and perfect leakage conditions, drug release in a semi-solid matrix is governed by pure diffusion, and the cumulative release per unit area is proportional to the square root of time.

The cumulative release Q is equal to the square root of twice the initial concentration C0 multiplied by the ratio of the diffusion coefficient D to time t, i.e., Q = K × √t.

Where K is the in vitro release rate constant (i.e., the slope of the regression line). When comparing drug names or generic drugs, the FDA SUPAC-SS guidelines require that the ratio of the release slopes of the two drugs be calculated using the Mann-Whitney method, and its 90% confidence interval must strictly fall between 75% and 133.33% in order to claim that the microstructure and release characteristics are consistent.

2. Transcutaneous flux dynamics model (Flux Profile) of IVPT

IVPT uses a limited dosage to simulate real human application, requiring the drug to undergo diffusion, distribution, and tissue adsorption through the stratum corneum. Its penetration flux J(t) is defined as the rate of drug mass transfer through a unit area of skin per unit time.

J(t) = (1 / A) × (dM / dt), where A is the effective area of the diffusion pool and dM/dt is the rate of change of the amount of body fluid accumulated over time.

A typical IVPT curve consists of three stages:

• Lag Phase: The time difference between when a drug penetrates the stratum corneum from the matrix and when it is first detected by the receptor fluid.

• Steady-state penetration and peak flux (Jmax): The drug penetration rate reaches its maximum value, corresponding to the peak of clinical drug absorption.

• Depletion Phase: The flux gradually decreases over time due to the depletion of the limited dose or the evaporation and drying of the prescription moisture.

IV. Regulatory Compliance and Automation Instrument Configuration Recommendations (Professional Support from Chinwei Technology)

To obtain internationally recognized IVRT and IVPT data, instrument hardware is crucial in terms of temperature uniformity (precisely maintaining 32.0 ± 1.0°C on the skin surface), consistency of the agitated flow field, bubble-free removal mechanism, and accuracy of micro-automatic sampling.

Chinwei Technology provides comprehensive original manufacturer solutions for transdermal absorption laboratories:

1. Vertical diffuser series (Logan System 913 / 914 / 918)

• Patented Bubble-Free Lateral Sampling Arm: Completely eliminates sub-membrane bubble residue, ensuring 100% wetting of the diffusion interface.

• The dry-heating DHC-6TD features precise direct heating temperature control: room temperature up to 50°C (±0.2°C), eliminating the risk of bacterial contamination from traditional water bath pipes. Each pool has independent magnetic stirring control.

• DSC-800 Smart Sampling Workstation: Integrates a precision push-pull injection pump to achieve isothermal and equal-volume fully automatic refill sampling, perfectly meeting the intensive sampling needs of IVRT.

2. Next-generation circulation pool system (Logan FTC-800 Flow-Through Diffusion System)

• Designed specifically for IVPT and ultra-micro penetration samples: compliant with USP <1724> flow cell specifications.

• Dual 8-channel micro-injection pumps: provide ultra-stable, pulse-free continuous flow from 0.1 to 4.0 mL/min, directly carrying the receiving vial for micro-dispensing, perfectly supporting downstream LC-MS/MS micro-volume analysis.

• PEEK corrosion-resistant tank body and automatic tilting venting support: ensures tight and smooth skin tissue and bubble-free flow path.

3. Data integrity compliance

• The entire series of workstations complies with FDA 21 CFR Part 11 and ALCOA+ principles, features electronic signatures, multi-level permissions and tamper-proof audit trails, and provides standard IQ/OQ validation documentation.

V. Conclusion

• IVRT stands for "Quality Mirror" : using synthetic membranes to exclude physiological variations, it purely examines the consistency of the substrate's physicochemical properties with the production process. It is a legally mandated test for CMC process changes and quality release.

• IVPT is a "clinical bridge" : using ex vivo skin and human topical dosages, it delves into the dynamics of drug crossing physiological barriers and is a key tool for the development of new topical drugs, bioequivalence (BE) waivers, and the establishment of intravitreal predictive models (IVIVC).

Professional consultation and online sample testing planning

Welcome to visit the DS website by clicking the link below, or fill out the online consultation form. Our professional technical consultants will plan a customized regulatory compliance and equipment selection solution for your laboratory.

• Official website : www.dissolution.com.tw

• Product Section : USP1724 Transdermal Absorption

• Technical consultation hotline : 04-2241-1607